__

Power 3 Medical Products Inc. (OTC BB: PWRM) recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene. PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

PROS (NYSE: PRO), the world leader in business-to-business pricing and margin optimization software, will host a pricing summit for executives on July 27, 2010 in Chicago. Executives from global business-to-business manufacturing and distribution companies attending the event will learn from real world examples and industry experts about how price analytics, optimization, and management as well as profitability management can significantly improve profit margins in this challenging financial environment.

TransMontaigne Partners L.P. (NYSE:TLP) reported that on July 16, 2010 it declared a distribution of $0.60 per unit for the period from April 1, 2010 through June 30, 2010. This distribution is payable on August 10, 2010 to unitholders of record on July 30, 2010.

Vitacost.com, Inc. (NASDAQ: VITC), a leading online retailer and direct marketer of health and wellness products, reported that Great Hill Investors, LLC, Great Hill Equity Partners III, L.P., and Great Hill Equity Partners IV, L.P. (“GHP”), has delivered to the company and its registered agent written consents from holders of the Company’s outstanding common stock as of the June 2, 2010 record date for GHP’s consent solicitation. Although the votes have not yet been certified, GHP has indicated to the company that such written consents represent votes from record holders of a majority of the outstanding shares of common stock (i) “for” amending the company’s bylaws to permit the company’s stockholders to fill vacancies on the company’s board of directors; (ii) “for” the removal of incumbent company directors – Messrs. Ezra, Gitler, Ilfeld and Pabst; (iii) “for” the election as company directors of Messrs. Gaffney, Jung, Kumin, and Stibel.

**************************************************************

Sign up to receive FREE stock alerts from PennyOmega.com at http://www.PennyOmega.com/signup

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).